JP5913307B2 - 多機能性抗体複合体 - Google Patents

多機能性抗体複合体 Download PDF

Info

Publication number
JP5913307B2
JP5913307B2 JP2013519199A JP2013519199A JP5913307B2 JP 5913307 B2 JP5913307 B2 JP 5913307B2 JP 2013519199 A JP2013519199 A JP 2013519199A JP 2013519199 A JP2013519199 A JP 2013519199A JP 5913307 B2 JP5913307 B2 JP 5913307B2
Authority
JP
Japan
Prior art keywords
antibody
seq
aspects
mac
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013519199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534535A (ja
JP2013534535A5 (enExample
Inventor
バト，アディジト・スレシュ
ブラッドショー，カート・ウィリアム
ローラン，オリヴィエ・アレクサンドル
リー，アリス
プレストン，リチャード・ライアン
タメルティ，デーヴィッド
ウッド，ローレン・ダイアン
ユ，ウェイ・ホン
Original Assignee
コヴェックス・テクノロジーズ・アイルランド・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コヴェックス・テクノロジーズ・アイルランド・リミテッド filed Critical コヴェックス・テクノロジーズ・アイルランド・リミテッド
Publication of JP2013534535A publication Critical patent/JP2013534535A/ja
Publication of JP2013534535A5 publication Critical patent/JP2013534535A5/ja
Application granted granted Critical
Publication of JP5913307B2 publication Critical patent/JP5913307B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013519199A 2010-07-12 2011-07-11 多機能性抗体複合体 Active JP5913307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36350710P 2010-07-12 2010-07-12
US61/363,507 2010-07-12
PCT/IB2011/053092 WO2012007896A1 (en) 2010-07-12 2011-07-11 Multifunctional antibody conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015248537A Division JP6339995B2 (ja) 2010-07-12 2015-12-21 多機能性抗体複合体

Publications (3)

Publication Number Publication Date
JP2013534535A JP2013534535A (ja) 2013-09-05
JP2013534535A5 JP2013534535A5 (enExample) 2014-03-20
JP5913307B2 true JP5913307B2 (ja) 2016-04-27

Family

ID=44630490

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013519199A Active JP5913307B2 (ja) 2010-07-12 2011-07-11 多機能性抗体複合体
JP2015248537A Active JP6339995B2 (ja) 2010-07-12 2015-12-21 多機能性抗体複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015248537A Active JP6339995B2 (ja) 2010-07-12 2015-12-21 多機能性抗体複合体

Country Status (19)

Country Link
US (1) US8741291B2 (enExample)
EP (1) EP2593142B8 (enExample)
JP (2) JP5913307B2 (enExample)
KR (1) KR20130050966A (enExample)
CN (1) CN103096933A (enExample)
AR (1) AR082205A1 (enExample)
AU (1) AU2011277999A1 (enExample)
BR (1) BR112013000951A2 (enExample)
CA (1) CA2804185C (enExample)
CO (1) CO6670522A2 (enExample)
ES (1) ES2704223T3 (enExample)
MX (1) MX2013000491A (enExample)
PE (1) PE20130643A1 (enExample)
PH (1) PH12013500070A1 (enExample)
RU (1) RU2012157167A (enExample)
SG (1) SG186451A1 (enExample)
TW (1) TWI432213B (enExample)
WO (1) WO2012007896A1 (enExample)
ZA (1) ZA201300161B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504893A (ja) * 2012-01-09 2015-02-16 コヴェックス・テクノロジーズ・アイルランド・リミテッド 変異抗体およびそのコンジュゲーション

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013118441A (ru) 2010-11-05 2014-12-10 КовЭкс Текнолоджиз Айэлэнд Лимитед Антидиабетические соединения
CA2836927A1 (en) * 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
PT3327027T (pt) 2011-11-17 2021-02-15 Pfizer Péptidos citotóxicos e seus conjugados de anticorpos e fármacos
KR102498405B1 (ko) 2012-10-11 2023-02-09 다이이찌 산쿄 가부시키가이샤 글리신아미드 화합물의 제조 방법
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
AU2013343111A1 (en) 2012-11-07 2015-05-14 Pfizer Inc. Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates
BR112015010436A2 (pt) 2012-11-07 2017-08-22 Pfizer Anticorpos anti-notch3 e conjugados anticorpo-fármaco
AU2013342163B2 (en) 2012-11-08 2018-08-16 F. Hoffmann-La Roche Ltd IL-6 antagonists and uses thereof
EP2922818B1 (en) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2015057066A1 (en) * 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
EP2935608A1 (en) * 2013-10-14 2015-10-28 SynAffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
PT3088419T (pt) 2013-12-25 2019-01-11 Daiichi Sankyo Co Ltd Conjugado de anticorpo anti-trop2-fármaco
CA2928794C (en) * 2014-01-31 2019-08-13 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
AU2014384434B2 (en) 2014-02-28 2016-11-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
WO2015155976A1 (ja) 2014-04-10 2015-10-15 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート
RU2711640C2 (ru) 2014-04-10 2020-01-17 Дайити Санкио Компани, Лимитед Конъюгат анти-her3 антитело-лекарственное средство
DK4268843T3 (da) 2014-11-07 2025-11-10 F Hoffmann La Roche Ltd Forbedrede IL-6-antistoffer
CA2986486C (en) * 2015-05-20 2023-03-07 Immunwork Inc. Molecular constructs with targeting and effector elements and their applications
LT3310816T (lt) * 2015-06-19 2020-11-25 Eisai R&D Management Co., Ltd. Cys80 konjuguoti imunoglobulinai
CN107922477B (zh) 2015-06-29 2022-11-01 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
TWI617319B (zh) * 2015-09-01 2018-03-11 免疫功坊股份有限公司 用以治療病理性血栓的融合蛋白
US11197934B2 (en) * 2015-09-17 2021-12-14 The Scripps Research Institute Dual variable domain immunoconjugates and uses thereof
AU2016341321A1 (en) * 2015-10-23 2018-06-07 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
US20220008553A1 (en) * 2015-11-23 2022-01-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
EP3413921A4 (en) 2016-02-09 2019-08-14 Alexander Krantz LOCAL ACTIVE FUNCTIONALIZATION OF PROTEINS BY MEANS OF TRANSPARENT AFFINITY MARKINGS
US20190046642A1 (en) * 2016-02-23 2019-02-14 Eleven Biotherapeutics, Inc. Il-6 antagonist formulations and uses thereof
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
KR102537651B1 (ko) 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
CA3051038C (en) 2017-01-24 2022-07-26 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
TW202530219A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
WO2019044946A1 (ja) 2017-08-31 2019-03-07 第一三共株式会社 抗体－薬物コンジュゲートの新規製造方法
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
JP2021502418A (ja) * 2017-11-04 2021-01-28 アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド ポリペプチドを修飾するための組成物及び方法
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
US12220604B2 (en) 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2021533200A (ja) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
KR20220045047A (ko) * 2019-08-19 2022-04-12 션양 파마슈티컬 유니버시티 항체 변이체 및 이의 적용
EP4025255A1 (en) 2019-09-04 2022-07-13 Bolt Biotherapeutics, Inc. Immunoconjugate synthesis method
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023288033A1 (en) 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
IL312142A (en) * 2021-11-01 2024-06-01 Dyne Therapeutics Inc Muscle targeting complexes for the treatment of dystrophinopathy
KR20250004769A (ko) * 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 그의 용도
KR20250004770A (ko) 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제
JP2025537044A (ja) 2022-09-30 2025-11-13 シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド ベンザゼピン誘導体、それを含む複合体およびその応用
CN120603814A (zh) 2023-02-28 2025-09-05 四川科伦博泰生物医药股份有限公司 一类化学偶联连接子及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
WO2001027145A1 (en) 1999-10-08 2001-04-19 The Scripps Research Institute Antibody catalysis of enantio- and diastereo-selective aldol reactions
AR032028A1 (es) 2001-01-05 2003-10-22 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
KR20040058229A (ko) 2001-10-22 2004-07-03 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
US7217845B2 (en) * 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
CN1835975B (zh) 2003-08-13 2012-11-21 辉瑞产品公司 经修饰的人类igf-1r抗体
JP5167473B2 (ja) 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
KR20120043028A (ko) 2006-11-10 2012-05-03 씨오브이엑스 테크놀로지스 아일랜드 리미티드 혈관 신생 억제 화합물
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CN101842117A (zh) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 抗igf-1r抗体及其用途
GEP20156390B (en) 2008-01-03 2015-11-10 Scripps Research Inst Antibody targeting through a modular recognition domain
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015504893A (ja) * 2012-01-09 2015-02-16 コヴェックス・テクノロジーズ・アイルランド・リミテッド 変異抗体およびそのコンジュゲーション

Also Published As

Publication number Publication date
MX2013000491A (es) 2013-02-26
EP2593142A1 (en) 2013-05-22
AR082205A1 (es) 2012-11-21
JP2016094455A (ja) 2016-05-26
KR20130050966A (ko) 2013-05-16
EP2593142B8 (en) 2018-12-26
CO6670522A2 (es) 2013-05-15
JP6339995B2 (ja) 2018-06-06
US8741291B2 (en) 2014-06-03
TW201216986A (en) 2012-05-01
ZA201300161B (en) 2013-09-25
CA2804185A1 (en) 2012-01-19
WO2012007896A1 (en) 2012-01-19
BR112013000951A2 (pt) 2016-05-17
AU2011277999A1 (en) 2013-01-10
EP2593142B1 (en) 2018-10-10
US20120201809A1 (en) 2012-08-09
JP2013534535A (ja) 2013-09-05
CA2804185C (en) 2017-03-21
CN103096933A (zh) 2013-05-08
PE20130643A1 (es) 2013-06-07
SG186451A1 (en) 2013-01-30
PH12013500070A1 (en) 2017-08-23
RU2012157167A (ru) 2014-08-20
TWI432213B (zh) 2014-04-01
ES2704223T3 (es) 2019-03-15

Similar Documents

Publication Publication Date Title
JP6339995B2 (ja) 多機能性抗体複合体
CN108473591B (zh) 位点特异性her2抗体药物缀合物
CN110382535A (zh) 抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
CN116617410A (zh) 用于癌症治疗的axl特异性抗体药物缀合物
KR20210141630A (ko) 항 her2 항체-피롤로벤조디아제핀 유도체 콘주게이트
WO2022001864A1 (zh) 一种抗体-药物偶联物，其制备方法及应用
US10112999B2 (en) Anti-PRLR antibody-drug conjugates (ADC) and uses thereof
HK1257352A1 (zh) 靶向gcc的抗体-药物缀合物
TW202421137A (zh) 靶向ＮａＰｉ２ｂ之抗體—藥物結合物及使用方法
CN118510806A (zh) 抗受体酪氨酸激酶EphA5的抗体-药物缀合物
CN114025795A (zh) 使用靶向her2的双特异性抗原结合构建体治疗胆道癌的方法
TW202237135A (zh) 抗體-吡咯并苯并二氮呯衍生物結合物
KR101770559B1 (ko) EGFR에 특이적으로 결합하는 Fab 단편
HK1188384A (en) Multifunctional antibody conjugates
TW202442681A (zh) 抗ror1抗體及其藥物偶聯物
CN121181699A (zh) 靶向cdh17的抗体和adc及其应用
CN118791622A (zh) 抗ror1抗体及其药物偶联物
KR20250111039A (ko) c-Kit 및 VEGF에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
WO2025242039A1 (zh) 抗cdh17抗体、其抗体药物偶联物及其用途
WO2025228351A1 (zh) 抗体，抗体药物偶联物及其用途
WO2025026338A1 (zh) 具有高药物负载的抗体-药物缀合物及其用途
HK40068270A (en) Methods of using a bispecific antigen-binding construct targeting her2 for the treatment of biliary tract cancers
HK1258498A1 (en) Site specific her2 antibody drug conjugates
HK1258498B (en) Site specific her2 antibody drug conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160401

R150 Certificate of patent or registration of utility model

Ref document number: 5913307

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250